Affluent Medical announces coverage initiation of its stock by Portzamparc – Groupe BNP Paribastifs

Aix-en-Provence, November 27, 2023 – 7:30 am CEST- Affluent Medical (ISIN code: FR0013333077 – ticker: AFME), a French clinical-stage MedTech company specializing in the international development and industrialization of innovative medical prostheses, announces today that Portzamparc - Groupe BNP Paribas has initiated coverage of its stock.

Portzamparc - BNP Paribas Group began covering the stock with a study entitled "Au plus proche de votre coeur" ("Closer to your heart"), published on November 24, 2023. In this study, Portzamparc - BNP Paribas Group recommended buying the stock, with a target price of €3.60, representing a potential upside of 188% compared with the closing price on November 23, 2023.

This initiation completes the coverage of Affluent Medical's stock and adds to the financial analyst consensus alongside Invest Securities and Kepler Cheuvreux.

About Affluent Medical

Affluent Medical is a French MedTech company, founded by Truffle Capital, with the ambition to become a global leader in the treatment of structural heart diseases, which are the world's leading cause of mortality, and urinary incontinence, which currently affects one in four adults.

Affluent Medical develops next-generation, mini-invasive, innovative, adjustable, and biomimetic implants to restore critical physiological functions. The product candidates developed by the Company are currently in preclinical and clinical studies.

Kalios, the first mitral adjustable annuloplasty ring, should be the first Affluent Medical device to be marketed.

Subject to raising the necessary funds to finance its strategy and to positive results from ongoing clinical studies, the Company's ambition is to gradually commercialize its products from the end of 2025/early 2026.

For more information, visit www.affluentmedical.com

Contacts: